Product Information
QUETIAPINE FUMARATE 200 MG TAB is a generic product labeled by Ascend Laboratories, LLC, priced at $0.0896 per EA under NDC 67877024610. Its NADAC has been published 585 times since Jul 22, 2015.
FDA first approved this application on Feb 12, 2013. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
200 mg/1
Manufacturer
Ascend Laboratories, LLCNDC
67877024610
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
QUETIAPINE FUMARATEApproval Type
Generic (ANDA)
FDA Application
ANDA201504FDA Approved
2/12/2013
TE Code
AB
On Market Since
3/1/2013
Pharmacological Classes
Price Statistics
The NADAC for QUETIAPINE FUMARATE 200 MG TAB has been published 585 times since Jul 22, 2015, and over the history we have for it it has declined 64.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0896 per EA |
|---|---|
| All-time high | $0.2607 (May 11, 2016) |
| All-time low | $0.0790 (Nov 20, 2024) |
| 52-week high | $0.0964 |
| 52-week low | $0.0845 |
| Median price | $0.1190 |
| Average price | $0.1363 |
| Largest weekly change | +32.4% (Jun 19, 2024) |
| Weeks tracked | 585 |
| Tracking since | Jul 22, 2015 |
Generic Alternatives
The matcher finds 11 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 2% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Ascend Laboratories, LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Quetiapine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Atypical Antipsychotic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of QUETIAPINE FUMARATE 200 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for QUETIAPINE FUMARATE 200 MG TAB, manufactured by Ascend Laboratories, LLC, is $0.0896 per EA (NDC 67877024610), effective Sep 30, 2026.
How has the price of QUETIAPINE FUMARATE 200 MG TAB changed over time?
Over the history we have for it, the NADAC for QUETIAPINE FUMARATE 200 MG TAB has declined 64.8%. It has been tracked across 585 weekly CMS publications since Jul 22, 2015.
What are the highest and lowest recorded NADAC prices for QUETIAPINE FUMARATE 200 MG TAB?
Since Jul 22, 2015, the NADAC for QUETIAPINE FUMARATE 200 MG TAB has ranged from a low of $0.0790 (Nov 20, 2024) to a high of $0.2607 (May 11, 2016), with a median of $0.1190 per EA.
Are there cheaper alternatives to QUETIAPINE FUMARATE 200 MG TAB?
Yes. 11 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, QUETIAPINE FUMARATE 200 MG TAB, is $0.0882 per EA — about 2% below QUETIAPINE FUMARATE 200 MG TAB.
Who manufactures QUETIAPINE FUMARATE 200 MG TAB?
QUETIAPINE FUMARATE 200 MG TAB (NDC 67877024610) is labeled by Ascend Laboratories, LLC, and CMS classifies it as a generic product.